Mesoblast Announced Tuesday It Requested A Trading Halt Pending Announcement Related To FDA's Review Of Its Biologics License Application Resubmission For Remestemcel-l In The Treatment Of Children With Steroid-refractory Acute Graft Versus Host Disease
Portfolio Pulse from Charles Gross
Mesoblast has requested a trading halt pending an announcement related to the FDA's review of its Biologics License Application resubmission for Remestemcel-l, a treatment for children with steroid-refractory acute graft versus host disease. The halt on U.S. shares took effect at 7PM ET on Tuesday.
August 04, 2023 | 10:43 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mesoblast's trading halt pending FDA review of its Biologics License Application resubmission for Remestemcel-l could cause uncertainty among investors, potentially impacting the stock's price.
The trading halt is directly related to Mesoblast's pending FDA review. This could cause uncertainty among investors as they await the outcome, which could potentially impact the stock's price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100